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Abstract: Tamoxifen is widely used for endocrine treatment and breast cancer prevention. It acts as both an estrogen 
antagonist in breast tissue and an estrogen agonist in the female lower genital tract. Tamoxifen causes severe gynecologic 
side effects, such as endometrial cancer. This review focuses on the effects of prolonged tamoxifen treatment on the human 
female genital tract and considers its tumorigenicity in the gynecologic organs through clinical data analysis. Tamoxifen is 
associated with an increased incidence of benign endometrial lesions such as polyps and hyperplasia and a two- to four-fold 
increased risk of endometrial cancer in postmenopausal patients. Moreover, the incidence of functional ovarian cysts is 
signiﬁ  cantly high in premenopausal tamoxifen users. To prevent tamoxifen from having severe side effects in gynecologic 
organs, frequent gynecological examination should be performed for both premenopausal and postmenopausal patients with 
breast cancer who are treated with this drug.
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Introduction
Tamoxifen is a nonsteroidal triphenylethyl compound that belongs to a class of selective estrogen recep-
tor modulators (SERMs) (Fig. 1), binds to estrogen receptors (ERs) and elicits estrogen agonist or 
antagonist responses, depending on the target tissue (Fig. 2) (MacGregor and Jordan, 1998; Pasqualini 
et al. 1998). Its estrogen antagonist properties have made tamoxifen an important treatment modality for 
patients with breast cancer, especially those whose tumors are positive for ERs. At present, tamoxifen is 
one of the most widely prescribed drugs in the world (ACOG Committee Opinion, 2006).
Tamoxifen was approved in 1977 by the US Food and Drug Administration for the treatment of 
metastatic breast cancer in postmenopausal patients. Tamoxifen was also found to suppress ER-positive 
breast cancer in postmenopausal women, to increase the disease-free interval, and to reduce the incidence 
of contralateral breast cancer in breast cancer patients (Early Breast Cancer Trialists’ Collaborative Group, 
1992). It is also effective in premenopausal breast cancer patients (Osborne, 1998; Clarke, 2006). Early 
treatment for breast cancer metastasis has been found to delay disease progression (Nicolini et al. 1997). 
Currently, tamoxifen is an option along with aromatase inhibitors as the endocrine treatment of choice 
in all stages of breast cancer in both pre- and postmenopausal women (Osborne, 1998; Clarke, 2006). 
Fisher and colleagues, (1989) recommended that all low-risk patients with breast cancer receive adjuvant 
therapy, and a large number of premenopausal and postmenopausal women have been placed on 3- to 
5-year regimens of tamoxifen. In addition, prophylactic use of tamoxifen resulted in a 45% reduction in 
the incidence of ER-positive breast cancer in healthy women, according to the Breast Cancer Prevention 
Trial of the National Surgical Adjuvant Breast and Bowel Project (Fisher et al. 1998). Therefore, in 1998 
the US Food and Drug Administration approved the use of tamoxifen as a chemopreventive option in 
both premenopausal and postmenopausal women.
Efﬁ  cacy of tamoxifen in breast cancer is due to its anti-estrogen properties, but it may also exert a weak 
estrogenic effect resulting in a variety of lesions in the female genital tract. Many ex vivo and in vivo stud-
ies have shown quite strong estrogenic-like activity in the endometrium, vagina, liver, and bones (Patterson 
et al. 1982; Wolf and Jordan, 1992). Tamoxifen blocks ERs in the hypothalamus, leading to the inhibition 
of estrogen feedback, which leads to increases in the production of gonadotropin-releasing hormone (GnRH), 
follicle-stimulating hormone (FSH), and luteinizing hormone (LH). Consequently, the ovaries may become 
hyperstimulated, form cysts, and produce more estrogen. FSH and LH levels ﬂ  uctuated during the treatment 
period. Estradiol (E2) levels were signiﬁ  cantly higher in the study group than in the control group (Sherman 18
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et al. 1979). Conversely, tamoxifen manifests estro-
gen agonist activity in the skeleton and uterus, as 
well as on a number of intermediate markers of 
cardiovascular risk.
Tamoxifen has long been considered a safe 
medication with few serious side effects. However, 
it has become clear in the past decade that pro-
longed use of this agent is associated with 
Figure 2. Pleiotropic effects of tamoxifen pointing to organ-speciﬁ  c beneﬁ  cial or deleterious effects.
Figure 1. Molecular structure of tamoxifen.19
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signiﬁ  cant gynecological complications (Table 1). 
The potential adverse effects of the drug include 
the development of endometrial cancer (Killackey 
et al. 1985; Fisher et al. 1994; Clarke et al. 1998; 
Bernstein et al. 1999), endometrial polyps (Corley 
et al. 1992; Lahti et al. 1993; Kedar et al. 1994), 
adenomyomatous polyp (Nasu et al. 1997), adeno-
myosis (Cohen et al. 1995), leiomyoma (Dilts et al. 
1992; Leo et al. 1994; Kang et al. 1996), cervical 
polyps, and ovarian cysts (Sawka et al. 1986; 
Cohen et al. 1994a; Barbieri et al. 1993; Shushan 
et al. 1996a; Terada et al. 1993; Nasu et al. 1999). 
Of these diseases, tamoxifen-associated endome-
trial pathologies have been evaluated exclusively. 
There is sufﬁ  cient clinical data to suggest that 
postmenopausal tamoxifen therapy may increase 
the risk of developing benign and malignant endo-
metrial pathologies (Cohen et al. 1998a). It is 
interesting that some of these ovarian cysts are 
functional, such as follicular or luteinized cysts 
(Dilts et al. 1992; Barbieri et al. 1993; Shushan et al. 
1996a; Terada et al. 1993). Tamoxifen was listed in 
1996 as a human carcinogen by the International 
Agency of Research on Cancer (International 
Agency of Research on Cancer, 1996).
This review focuses on the effects of prolonged 
tamoxifen treatment on the adult human female 
genital tract and considers its tumorigenicity in 
the gynecologic organs based on an analysis of 
clinical data.
Action Mechanism of Tamoxifen
on Target Organs
Tamoxifen binds to the ER with a Kd of  2 nM, 
which is ∼20-fold lower than that of 17β-estradiol 
(Capony and Rochefort, 1978). Administered as a 
single oral dose of 20 mg, tamoxifen is rapidly 
absorbed, with its concentration peaking in ∼5 
hours. The terminal elimination half-life is ∼5–7 
days. Steady-state concentrations in plasma are 
reached after ∼4 weeks of tamoxifen therapy in 
women. Tamoxifen is extensively metabolized 
after oral administration: ∼65% of the administered 
dose is excreted over 2 weeks, primarily through 
the feces. Tamoxifen is excreted mainly as polar 
conjugates, which account for ∼70% of the elimi-
nation products. Tamoxifen is hydrated by cyto-
chrome P450 (CYP) 2D6 to the potent metabolites 
4-hydroxytamoxifen and 4-hydroxy-N-desmethyl 
tamoxifen (endoxifen). The major metabolite, 
4-hydroxy-N-desmethyl tamoxifen, is similar in 
biological activity to tamoxifen (Zeneca 
Pharmaceuticals, 1998). CYP2D6 activity is con-
sidered as a determinant of tamoxifen efﬁ  cacy and 
adverse effects (Goetz et al. 2005). Breast cancer 
patients who were poor metabolizers of CYP2D6 
had a worse clinical outcome and fewer adverse 
effects compared with those who were extensive 
metabolizers of CYP2D6.
The cell-speciﬁ  c effects of tamoxifen in geni-
tal tissues and its divergent effects in premeno-
pausal and postmenopausal women are complex, 
thus making it difﬁ  cult to determine what deﬁ  nes 
the biologic effect (i.e. agonist or antagonist) on 
a speciﬁ  c gynecologic organ or tissue. Tamoxifen 
also interacts with cellular proteins other than the 
estrogen receptor, such as protein kinase C, 
calmodulin, transforming growth factor-β, 
insulin-like growth factor-I, phosphoinositide 
kinase, P-glycoprotein, and membrane-associated 
proteins through the ER-independent pathway 
(Lam, 1984; O’Brian et al. 1985; Butta et al. 
1992; Laatikainen et al. 1995; Cabot et al. 1997; 
Duk et al. 1997; Elkas et al. 1998; Friedman, 
1998; Zhao et al. 1998).
In 1996, a second isoforms, ERβ, was discov-
ered (Kuiper et al. 1996; Mosselman et al. 1996). 
One possible explanation for the tissue-selective 
activity of different ER ligands is that they interact 
with different receptors. In addition, splice variants 
of each of these receptors have been observed, 
allowing them to express various isoforms of ERα 
and ERβ in different tissues (Ogawa et al. 1998). 
ERβ is expressed in tissues other than ERα, and 
both ERs have different ligand binding properties. 
Table 1. Summary of the incidence of tamoxifen-associated gynecological malignancies.
Site  Tumor type  Incidence/No.  Status   References
    of reported cases  of menstruation 
Ovary  Adenocarcinoma  One case  Postmenopausal  Cohen et al. 1994b
Uterus Endometrial  cancer  0.2−0.3%  Postmenopausal   Assikis and Jordan 1995
  Sarcoma   17/100,000  Not described  Wickerham et al. 200220
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These differences might contribute to the selective 
action of tamoxifen and other SERMs in different 
tissues. ERβ transcripts have been detected in 
tissues such as prostate, ovaries, and lungs, as well 
as in various parts of the central and peripheral 
nervous systems. In contrast, ERα is predomi-
nantly detected in the pituitary gland, ovaries, 
uterus, kidneys, adrenals, and mammary glands 
(Kuiper et al. 1996; Kuiper and Gustafsson, 1997). 
These differences in the distribution of ERα and 
ERβ may explain the selectivity of the compounds. 
Tamoxifen has a similar afﬁ  nity to both receptors 
(Kuiper and Gustafsson, 1997). Some scientists 
believe that uterotrophic activity of tamoxifen is 
caused by ERβ. Both receptors have identical 
DNA-binding domains, but within the ligand-
binding domain, the amino acid sequence diverges 
considerably (Kuiper et al. 1996; Kuiper and 
Gustafsson, 1997) (Fig. 3). Thus, although both 
receptors have an equivalent affinity to 17β-
estradiol with regard to other substances, there are 
important differences. Tamoxifen acts as an 
antagonist when both the transactivating domains, 
transcription activating function (TAF)-1 and 
TAF-2, are suppressed, but as an agonist when the 
TAF-1 activation overcomes TAF-2 inhibition.
Cell-speciﬁ  c effect of tamoxifen in the same 
tissue can be explained by the tripartite theory of 
Katzenellenbogen et al. (1996), who studied the 
pharmacologic basis for the cell-and promoter 
speciﬁ  c action of steroid hormones. They referred 
to the cell and tissue selectivity that steroid 
hormones display as a tripartite system comprising 
ligand, receptor, and effector. Their results showed 
that molecular elements within the cell nucleus 
interact with the ligand-receptor complex and 
influence ER transcriptional response to the 
ligand. The biocharacter of the ligand (i.e. agonist-
antagonist balance) is determined principally 
through this receptor-effector coupling (O’Brian 
et al. 1985). This molecular explanation of the 
agonistic and antagonistic effects of the ligand-
binded ER is further supported by others 
(Brzozowski et al. 1997; Parker, 1998). Hormone 
binding to the ligand-binding domain of the ER 
initiated a series of molecular events culminating 
in the activation or repression of target genes. Each 
ligand induces a distinct conformation in the 
transactivation domain, creating an interacting 
surface to which coactivators are likely to bind. 
Several candidate coactivating proteins have been 
identiﬁ  ed, including receptor-interacting proteins 
RIP-140 and RIP-160, L7SPA, and steroid recep-
tor coactivator-1 (SRC-1) (Onate et al. 1995; 
Horwitz et al. 1996; Jackson et al. 1997; Shah and 
Rowan, 2005). These proteins interact with recep-
tors only in the presence of their respective 
ligands, providing structural evidence for the 
Figure 3. Comparison of the two estrogen receptor molecules. The estrogen receptor consists of six functional domains. Estrogens manifest 
their biological activity through two distinct receptors, ERα and ERβ. The numbers in the boxes indicate numbers of amino acids. Homology 
between the distinct domains of the receptors is indicated. It is believed that the binding of different ligands induces structural alterations 
within the estrogen receptor and that the cells differ in their ability to recognize these conformations. TAF: transcription activating function.21
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mechanism of repression or activation of target 
genes (Parker, 1998).
Ovary
In breast cancer patients, ovarian cyst formation 
during prolonged tamoxifen treatment (Cohen et al. 
1994a; Barbieri et al. 1993; Kedar et al. 1994; 
Shulman et al. 1994; Nasu et al. 1999) and in series 
of tamoxifen-treated breast cancer patients (Cohen 
et al. 1996; Shushan et al. 1996a) has been reported. 
Ovarian cysts also have been described in a breast 
cancer prevention study (Powles et al. 1994). These 
reports described a heterogeneous group of ovarian 
pathologies with numerous histologic diagnoses, 
but they did not assess hormones or define 
menopausal status. In premenopausal patients, 
tamoxifen disrupts the menstrual cycle and causes 
functional ovarian cysts (Cohen et al. 1994a; 
Hochner-Celnikier et al. 1995). The ovarian pathol-
ogy in these instances includes simple cysts, 
follicular cysts, luteinized follicular cysts, and 
corpus luteum cysts (Cohen et al. 1994a; Hochner-
Celnikier et al. 1995; Shushan et al. 1996a). Some 
studies suggest that benign ovarian pathologies 
may be expected in most premenopausal tamoxifen 
users (Cohen et al. 1994a). It is interesting that 
these cysts regress if tamoxifen is withdrawn 
(Shushan et al. 1996a) or if premenopausal patients 
are treated with GnRH agonists during tamoxifen 
treatment (Cohen et al. 1994a; Shushan et al. 
1996b). These lesions, although benign, may be 
complicated by torsion or cystic necrosis and may 
pose a diagnostic dilemma in patients at risk of 
ovarian metastases from breast cancer or of primary 
ovarian cancer (Cohen et al. 1994a).
In premenopausal women, these cysts may be 
associated with hyperestrogenism (Cohen et al. 
1994a; Hochner-Celnikier et al. 1995). In the 
ovaries of premenopausal patients, tamoxifen 
stimulates estrogen production by affecting the 
hypothalamic-pituitary-ovarian feedback mecha-
nism (Kedar et al. 1994). The hyperestrogenemia 
described during tamoxifen therapy may reﬂ  ect a 
simultaneous maturation of multiple ovarian 
follicles or an enhanced gonadotropin stimulation 
of a single maturing follicle (Sherman et al. 1979). 
Such a phenomenon may lead to an increased risk 
of ﬁ  broid ovaries and ovarian cysts (Cohen et al. 
1994a). However, the mechanism by which 
tamoxifen stimulates the development of ovarian 
cysts has not yet been fully explored. It was 
suggested that the mechanism by which tamoxifen 
induces ovarian cysts in premenopausal women 
could be by a direct action on the ovaries to 
stimulate excessive growth of ovarian follicles, 
resulting in elevated estradiol levels (up to 
3,700 pg/ml), throughout all phases of the 
menstrual cycle (Terada et al. 1993). Mourits et al. 
(1999) performed a prospective study using 
transvaginal ultrasound with hormonal assessment 
and reported ovarian cysts in 40% of premenopausal 
women during tamoxifen treatment, whereas none 
of the postmenopausal patients developed cystic 
ovaries. In patients with regular menstrual cycles 
during tamoxifen treatment, 81% developed 
ovarian cysts. In these premenopausal women with 
cystic ovaries, the serum estrogen levels were 
markedly elevated, with gonadotropin concentra-
tions either unchanged or slightly increased.
Sawka et al. (1986) reported that 7 of 84 pre-
menopausal women being treated with tamoxifen 
for breast cancer developed cystic enlargement of 
the ovaries. It is uncertain how many of these cases 
will require surgical intervention. Shushan et al. 
(1996a) reported that 5 of 79 tamoxifen treated 
premenopausal women with breast cancer had 
cystic enlargement of the ovaries. They also 
reported that, in 8 of 11 patients, the ovarian cystic 
enlargement disappeared after the cessation of 
tamoxifen treatment. Barbieri et al. (1993) reported 
a case of a 45-year-old woman with breast cancer 
treated with tamoxifen for 2 years. She had bilateral 
functional ovarian cysts and torsion of unilateral 
adnexa, and underwent surgical treatment. Terada 
et al. (1993) also reported a case of a large ovarian 
follicular cyst with torsion, whose serum estradiol 
level was significantly increased. Sadan et al. 
(2001) reported that 7 of 10 (70%) women with 
tamoxifen administration developed ultrasono-
graphically benign ovarian cysts ranging from 1.5 
to 6.0 cm in diameter. One woman underwent 
surgery to remove an enlarging cyst. In all of the 
other patients, ovarian cysts disappeared within 
three months after the cessation of therapy. We 
have also reported the torsion of an ovarian func-
tional cyst in a premenopausal breast cancer patient 
who was treated surgically (Nasu et al. 1999).
Although torsion of a cystic ovary during tamox-
ifen treatment has been described (Barbieri et al. 
1993; Nasu et al. 1999), surgical intervention is 
rarely required, and functional asymptomatic mono-
locular cysts in these patients should be followed 
conservatively (Mourits et al. 2001). The discon-
tinuation of tamoxifen usually leads to the gradual 22
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reduction and disappearance of these lesions (Cohen 
et al. 1994a).
Whereas tamoxifen in postmenopausal patients 
induces ovarian cystic tumors and endometriomas 
(Kedar et al. 1994; Shushan et al. 1996a; Varras 
et al. 2003), Cohen et al. (1996) reported that 10 
of 16 tamoxifen-treated women who had under-
gone hysterectomy had ovarian neoplasms. Four 
of these women had serous cystadenomas, and two 
had serous cystadenofibromas. Other ovarian 
tumors in this group included an endometrioid 
adenocarcinoma (Cohen et al. 1994b), a Brenner 
tumor, a thecoma, and ovarian ﬁ  bromas. It is con-
troversial whether or not tamoxifen users risk 
developing ovarian cancer (Cohen et al. 1996; 
Ismail, 1999; Lewis 2000).
Uterine Corpus
Mechanism of endometrial
tumorigenesis
The possible mechanisms involved in the endome-
trial carcinogenicity of tamoxifen are quite 
complex. The molecular machinery involved in the 
induction of endometrial polyps, hyperplasia, and 
endometrial carcinoma by tamoxifen may differ 
from that of estrogens (Webb et al. 1995). Regard-
ing the action of tamoxifen in the endometrium, 
we propose this mechanism: tamoxifen binds to 
the ER in the estrogen-binding domain, located in 
the functional domain E of the ER, and forms 
dimers of activated ERs (receptor dimerization). 
These dimers bind to the specialized ER response 
elements (EREs) of the DNA in the endometrial 
cells. This binding allows the activation of the ER 
region TAF-1 function, which mediates the 
activation of the estrogen-independent transcrip-
tional activating function (Fig. 3). It has been 
reported that tamoxifen and its metabolites are 
concentrated in the endometrium, especially with 
hyperplastic changes (Giorda et al. 2000). The 
estrogenic activity of tamoxifen is cell type-speciﬁ  c 
in that it stimulates cell growth and the transcrip-
tion of a number of estrogen-regulated genes in the 
uterus but not in the breast (Ramkumar and Adler, 
1995; Webb et al. 1995). The mitogen function of 
tamoxifen in the endometrium is perhaps explained 
by the activation of proto-oncogenes, which occurs 
exclusively by the region TAF-1 function. In 
contrast, in the breast the expression of proto-
oncogenes depends on the region TAF-2 function, 
which is activated only by estrogens. The 
overexpression of proto-oncogenes caused by 
tamoxifen may be responsible for carcinogenesis 
in the endometrium. It has been reported that 
tamoxifen induces endometrial K-ras oncogene 
codon 12 mutations, which are considered impor-
tant in endometrial carcinogenesis (Sasaki et al. 
1993; Hachisuga et al. 2005; Wallen et al. 2005). 
Tamoxifen also modulates the expression of a vari-
ety of endometrial genes, including tumor protein 
p53, nuclear factor-κB transcription factor subunit 
p65 (RelA), myelocytomatosis viral oncogene 
homologue (myc), epidermal growth factor recep-
tor, and β-catenin (Gielen et al. 2005).
Tamoxifen is metabolized in the human liver to 
α-OH-tamoxifen, N-des-tamoxifen, tamoxifen 
N-oxide, and 4-hydroxytamoxifen (Randerath 
et al. 1994; Jarman et al. 1995). Among these 
tamoxifen metabolites, it is reported that α-OH-
tamoxifen is sulfonated by hydroxysteroid sulfo-
transferases (Shibutani et al. 1998a; Shibutani et al. 
1998b) and reacts with the exocyclic amino group 
of guanine in DNA, resulting in the formation of 
two trans and two cis diastereoisomers of α-
(N
2-deoxyguanoxinyl)tamoxifen (dG-N
2-tamoxi-
fen), which have been found in patients treated 
with tamoxifen (Shibutani et al. 1999). dG-N
2-
tamoxifen adducts display a high miscoding and 
mutagenic potential and generate primarily G- to 
T-transversions in mammalian cells (Shibutani and 
Dasaradhi, 1997; Terashima et al. 1999). Such 
tamoxifen adducts, if not repaired (Shibutani et al. 
2000b), may cause mutations, leading to the devel-
opment of endometrial cancers. Signiﬁ  cant levels 
of dG-N
2-tamoxifen adducts have been detected 
in the endometria of certain women treated with 
tamoxifen (Shibutani et al. 1999; Shibutani et al. 
2000a). The biotransformation of tamoxifen into 
α-hydroxytamoxifen, 4-hydroxytamoxifen, and 
N-desmethyltamoxifen has been demonstrated in an 
endometrial explant culture (Sharma et al. 2003). 
Kim et al. (2005) reported that the addition of 
α-hydroxytamoxifen to the endometrial explant cul-
ture induced tamoxifen-DNA adduct. In a study using 
the accelerator mass spectrometry, tamoxifen bound 
irreversibly to DNA, forming DNA adducts at low 
levels in the endometrium (Martin et al. 2003).
Clinical data indicate that tamoxifen therapy 
may cause an increased risk of endometrial pathol-
ogy in postmenopausal women but not in premeno-
pausal women. It has been demonstrated that 
tamoxifen exerts a proapoptotic effect on cultured 23
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endometrial cells in the presence of estrogen 
(Stackievicz et al. 2001). On the other hand, 
tamoxifen shows a weak anti-apoptotic effect on 
these cells in the absence of estrogen. In 2007, 
Singh et al. (2007) proposed a dual mechanism of 
action highlighted by the different patterns of 
endometrial carcinoma sub-types. Tamoxifen may 
initially be pro-estrogenic in the endometrium 
giving rise to elevated type-1 endometrioid adeno-
carcinoma, whereas after long-term use, there is 
an increase of type-2 disease or malignant mixed 
Müllerian tumors (MMMTs) associated with a 
hormone-independent mechanism of action.
Tamoxifen-induced endometrial 
pathology
Various histopathological ﬁ  ndings ranging from 
proliferative endometrium, hyperplasia, and polyps 
to carcinoma have been found in tamoxifen-treated 
patients. Combining the results of four prospective 
studies, Assikis and Jordan, (1995) reported polyps 
and hyperplasia in 16% of women on tamoxifen. 
Juneja et al. (2002) found polyps and hyperplasia 
in 20% of women on tamoxifen. It has been 
reported that two-thirds of the tamoxifen-treated 
patients have no pathologic endometrial changes 
and one-third have tamoxifen-associated endome-
trial changes including endometrial polyps, hyper-
plasia, metaplasia, and cancer (Deligdisch et al. 
2000). It has been reported that 10% of tamoxifen-
treated patients will develop tamoxifen-induced 
endometrial pathology within 5 years, leading to 
operative intention (Gerber et al. 2000).
In premenopausal women there is nearly no 
excess risk of adverse endometrial effects (Cheng 
et al. 1997; Fisher et al. 1998). Effect of tamoxifen 
on the endometrium varies with the ambient E2 
concentration in that it will function as an estrogen 
agonist only in postmenopausal women and thus 
may cause endometrial pathologies (Gal et al. 
1991; Lahti et al. 1993; Lahti et al. 1994; Cohen 
et al. 1994a; Kedar et al. 1994). The proliferative 
activity in benign endometrial epithelium is higher 
in tamoxifen users than in non-users (Elkas et al. 
2000; Mourits et al. 2002), suggesting that this 
phenomenon may play a role in the higher inci-
dence of endometrial cancer in postmenopausal 
tamoxifen users. Proliferative effect of tamoxifen 
on the endometrium has been supported by 
molecular data. The expression of both ER and 
PR was found to be consistently positive in 
endometria from women treated with tamoxifen 
(Cano and Hermenegildo, 2000). This positivity 
was reported to be even higher than that found in 
a control group of premenopausal women 
(Kommoss et al. 1998). Tamoxifen also mimicked 
estradiol treatment in upregulating ER, c-fos, and 
glyceraldehyde phosphate dehydogenase mRNAs, 
together with other estrogen-induced genes 
(Rivera-Gonzalez et al. 1998; Robertson et al. 
1998). The bromo-deoxyuridine index, an indica-
tor of cell mitogenesis, was shown to be increased 
in endometrial cells from tamoxifen-treated uteri 
(Carthew et al. 1999). In this connection, the 
expression of proliferation markers, e.g. Ki67, was 
potentiated by tamoxifen in human endometrium 
(Elkas et al. 1998). An increased susceptibility to 
genetic lesions associated with carcinogenesis 
linked to tamoxifen was suggested by a study on 
endometrium of surgically post-menopausal cyno-
molgus macaques, where the drug induced p53 
positivity, although at a lower level than conju-
gated estrogen (Isaksson et al. 1999).
Endometrial hyperplasia
An increased incidence of endometrial hyperplasia 
up to 50% has also been detected by some inves-
tigators in samples obtained from tamoxifen-
treated breast cancer patients compared with breast 
cancer patients not being treated with tamoxifen 
(Gal et al. 1991; Lahti et al. 1993). In a cohort of 
61 normal postmenopausal women recruited from 
the Pilot Breast Cancer Prevention Trial (Kedar 
et al. 1994), atypical hyperplasia was detected in 
16% of the tamoxifen-treated women.
Neven et al. (1989) found proliferative/hyper-
plastic features in the endometrium of 43% of 
tamoxifen-treated breast cancer patients compared 
with 14% of untreated patients. Cohen et al. (1993) 
found proliferative activity in 19 of 22 endometrial 
biopsies obtained from a series of 77 asymptomatic 
tamoxifen treated postmenopausal breast cancer 
patients. In a study of 16 breast cancer patients 
receiving tamoxifen, 7 women had mild prolifera-
tive endometrium after 16 months of treatment 
(Neven et al. 1990). The same group ultimately 
reported that 5 out of 57 women receiving tamox-
ifen developed clear endometrial hyperplasia or 
cancer; the endometrium remained atrophic in 24 
women (Neven et al. 1998).
On macroscopic examination, tamoxifen-
stimulated endometrial hyperplasia is characterized 
by diffuse endometrial thickening with a 24
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Swiss-cheese-like cut surface owing to the presence 
of multiple intraendometrial cysts of varying size 
(Ismail, 1994). Microscopic examination conﬁ  rms 
that there is diffuse endometrial thickening with 
cystically dilated glands, which are clearly of 
endometrial origin and located within the endome-
trium (Ismail, 1994) rather than beneath it, as has 
been suggested on the basis of ultrasonographic 
findings (Goldstein, 1994). Some endometrial 
glands show glandular budding and other architec-
tural abnormalities. Focally, the glandular epithe-
lium shows mitotic activity, and often also shows 
mucinous, clear cell, oxyphilic, and other epithelial 
metaplasias. The endometrial stroma is character-
istically ﬁ  brotic (Ismail, 1994; Ismail, 1996) with 
collagen bundles separating stromal cells (Ismail, 
1996). Occasional stromal mitoses may also be 
seen. These microscopic appearances, which indi-
cate an increase in the amount of endometrial tissue 
and a low but deﬁ  nite proliferative activity, are best 
interpreted as hyperplasia of the endometrium 
(Ismail, 1998). Zhao et al. (1998) have shown that 
endometria of women receiving tamoxifen express 
adrenomedullin, a growth factor for endothelial 
cells; they postulated that induction of this angio-
genic factor is part of the mechanism by which 
tamoxifen results in endometrial hyperplasia.
If the hyperplasia is atypical or complex, 
discontinuation of the drug is advisable. If 
tamoxifen has to be continued, hysterectomy may 
be an option.
Endometrial polyp
Many studies have shown a high frequency of 
endometrial polyps in tamoxifen-treated postmeno-
pausal breast cancer patients (Neven et al. 1989; 
De Muylder et al. 1991; Corley et al. 1992; Cohen 
et al. 1993; Lahti et al. 1993; Ismail, 1994; Kedar 
et al. 1994; Silva et al. 1994; Cheng et al. 1997; 
Cohen et al. 1999), but a low frequency of endo-
metrial polyps in tamoxifen-treated premenopausal 
patients (Hachisuga et al. 1999). Evidence of polyp 
formation is reported to occur in 8 to 50% of 
women on tamoxifen (Neven et al. 1989; Gal et al. 
1991; Lahti et al. 1993; Ismail, 1994; Kedar et al. 
1994), which exceeds the  4% observed in 
patients with breast cancer not receiving tamoxifen. 
Neven et al. (1989) reported a sevenfold increase 
in endometrial polyps among tamoxifen-treated 
asymptomatic breast cancer patients when 
compared with patients not treated with tamoxifen. 
A larger study by Lahti et al. (1993) found 
endometrial polyps in 36% of treated and 10% of 
untreated asymptomatic postmenopausal breast 
cancer patients. Although usually benign, such 
polyps differ histologically from non-tamoxifen-
exposed endometrial polyps.
Cohen et al. (2001) demonstrated that the risk 
factors for the development of endometrial polyps 
associated with tamoxifen therapy are older age at 
menopause, longer duration of breast cancer 
disease, heavier weight, and thicker endometrium. 
Especially, the long-tem tamoxifen therapy ( 48 
consecutive months) has been shown to increase 
the frequency of endometrial lesion, especially of 
endometrial polyps (Cohen et al. 1996).
Endometrial polyps that develop in tamoxifen-
treated women have unusual macroscopic and 
microscopic features (Nuevo et al. 1989; Corley 
et al. 1992; Ismail, 1994). Tamoxifen associated 
endometrial polyps tend to develop on a back-
ground of endometrial hyperplasia (Ismail, 1994). 
The polyps are often multiple and usually much 
larger than sporadic polyps (Nuovo et al. 1989; 
Corley et al. 1992; Ismail, 1994). They may 
undergo ulceration and infarction, and their 
consequent irregular friable appearance may mimic 
malignancy. Gross myxoid change is occasionally 
seen (Ismail, 1999). On microscopic examination, 
the polyps comprise abundant ﬁ  bromyxoid stroma 
and architecturally abnormal endometrial glands 
lined mostly by benign epithelium (Ismail, 1994; 
Neven, 1995; Deligdisch et al. 2000). Proliferative 
activity is commonly seen in both epithelial and 
stromal cells. The epithelial cells lining the glands 
show a range of metaplasias including apocrine, 
squamoid, mucinous, clear cell, and oxyphil cell 
metaplasia (Ismail, 1999). There is patchy conden-
sation of the stromal cells around the glands. It has 
been reported that Bcl-2 and Ki-67 expression was 
higher in tamoxifen-associated polyps than in 
postmenopausal untreated polyps (Altaner et al. 
2006). These ﬁ  ndings suggest that tamoxifen-
associated endometrial polyps have higher rates of 
cell mitotic activity and apoptosis inhibition; these 
higher rates may play a crucial role in the malignant 
transformation of such endometrial polyps.
A high prevalence of endometrial carcinoma 
arises from tamoxifen associated endometrial polyps 
(Cohen, 2004). From 3 to 10.7% of endometrial 
polyps resected from tamoxifen-treated postmeno-
pausal patients with breast cancer were found to 
experience malignant changes (Cohen et al. 1999). 25
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In contrast, only 4 endometrial carcinoma arising 
from endometrial polyps were found in a large study 
of 1,100 endometrial polyps carried out before the 
introduction of tamoxifen (Peterson and Novak, 
1956). Silva et al. (1994) showed that 77% of post-
menopausal patients who developed endometrial 
carcinoma after tamoxifen treatment had endome-
trial polyps, whereas 34% patients in a comparable 
group who did not receive tamoxifen had endome-
trial polyps. Deligdisch et al. (2000) reported that 
15 of 33 endometrial carcinomas that developed in 
postmenopausal breast cancer patients subsequent 
to adjuvant tamoxifen treatment were found in 
endometrial polyps. Nishimura et al. (2001) reported 
that 5 of 8 endometrial carcinomas in postmeno-
pausal breast cancer patients were associated with 
polypoid lesions composed of cystically dilated 
atrophic glands and ﬁ  brotic stroma and that no such 
polyps were found in 2 premenopausal patients. 
These ﬁ  ndings suggest that the polyp-carcinoma 
sequence plays a partial role in the development of 
endometrial carcinoma in tamoxifen-treated post-
menopausal breast cancer patients (Ismail, 1994).
Adenomyomatous polyp (polypoid adenomy-
oma) of the endometrium is a rare polypoid lesion 
in which the stromal component is largely or exten-
sively composed of smooth muscle (Peterson and 
Novak, 1956). A few cases of adenomyomatous 
polyps in a postmenopausal patient treated with 
tamoxifen have been reported (Cohen et al. 1995; 
Nasu et al. 1997; Takeuchi et al. 2005).
Endometrial cancer
Endometrial cancer is the most serious uterine 
condition associated with tamoxifen use. Killackey 
et al. (1985) reported the ﬁ  rst case of endometrial 
carcinoma in a breast cancer patient who was 
treated with tamoxifen. After that, a series of case 
reports suggested an association between 
tamoxifen and endometrial neoplasia (Jordan, 
1998). The ﬁ  rst prospective study was published 
by Neven et al. (1990). Of 16 postmenopausal 
women treated with tamoxifen for 3 years and 
followed thereafter by hysteroscopy, 50% main-
tained inactive atrophic endometrium, while 44% 
developed proliferation, including 25% polyps 
and 6% adenocarcinoma. It remains unclear as to 
whether tamoxifen, because of its estrogen ago-
nistic properties, induces the formation of endo-
metrial cancer or accelerates the growth of 
pre-existing endometrial cancer. A detection bias 
must also to be taken into account: gynecological 
symptoms induced by tamoxifen (vaginal 
discharge, abnormal bleeding) and/or tamoxifen-
related ultrasound phenomena (endometrial 
thickening) often lead to hysteroscopy, endome-
trial sampling and/or dilatation and curettage, 
which might detect latent endometrial cancer that 
would not have been found if the women had not 
shown these tamoxifen-induced gynecological 
symptoms (Baum, 1998).
The National Surgical Adjuvant Breast and 
Bowel Project (NSABP) prevention trial (P-1) data 
suggest that the risk ratio for developing endome-
trial cancer was 2.53 times greater in women using 
tamoxifen than in women receiving a placebo 
(Fisher et al. 1998). In addition, the ability of 
tamoxifen to induce endometrial malignancy as 
well as other histopathologic conditions appears 
to differ between premenopausal and postmeno-
pausal women. In the prevention trial of high-risk 
women, there was no statistically signiﬁ  cant dif-
ference in endometrial cancer rates between 
women treated with tamoxifen and those in the 
placebo group in women aged 49 years or younger; 
however, in women aged 50 or older, the risk ratio 
was 4.01 for those treated with tamoxifen versus 
those receiving placebo. The annual rate was 3.05 
malignancies per 1,000 women treated with 
tamoxifen versus 0.76 malignancies per 1,000 
women receiving placebo (Fisher et al. 1998). 
Another study of women with breast cancer found 
that premenopausal women, treated or untreated, 
had no differences in endometrial thickness on 
ultrasound examination, uterine volume, or histo-
pathologic findings, whereas postmenopausal 
women treated with tamoxifen had signiﬁ  cantly 
more abnormalities than those who were not treated 
(Cheng et al. 1997).
The risk of developing endometrial cancer in 
asymptomatic women is estimated at 1.7 per 1,000 
women-years (Koss, 1980). Most studies have 
found that the increased relative risk of developing 
endometrial cancer for women taking tamoxifen 
is two to four times higher than that of an age-
matched population (Lahti et al. 1993; Barakat 
et al. 1994; Cohen et al. 1994a; Fisher et al. 1994; 
Rutqvist et al. 1995; Curtis et al. 1996; Early Breast 
Cancer Trialists’ Collaborative Group, 1998). The 
overall incidence of endometrial cancer in 
tamoxifen-treated women has been quoted to be 
2–3/1,000 (Assikis and Jordan, 1995). The relative 
risk as calculated by three retrospective randomized 26
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clinical trials was 4.1 compared with controls. In 
one study of the NSABP, the rate of endometrial 
cancer occurrence among tamoxifen users who 
were administered 20 mg/day was 1.6 per 1,000 
patient years, compared with 0.2 per 1,000 patient 
years among control patients taking a placebo 
(Fisher et al. 1994). In a more recent update of 
NSABP trials of patients with breast cancer, the 
rate of endometrial cancer was 1.26 per 1,000 
patient years in women treated with tamoxifen 
versus 0.58 per 1,000 in the placebo group 
(Wickerham et al. 2002). The Stockholm breast 
cancer study group found a nearly six-fold increase 
in endometrial carcinomas in patients treated with 
40 mg/day tamoxifen for 2–5 years as compared 
with a control group (Rutqvist et al. 1995). The 
increased incidence of endometrial cancers was also 
observed in tamoxifen chemoprevention trials 
(Fisher et al. 1994; Fisher et al. 1998). It is now 
considered that the risk level for endometrial 
cancer in women treated with tamoxifen is dose- 
and time-dependent. Studies suggest that the stage, 
grade, histology, and biology of tumors that 
develop in individuals treated with tamoxifen 
(20 mg/day) are no different from those that arise 
in the general population (Fisher et al. 1994; Bara-
kat et al. 1994). However, some reports have 
indicated that women treated with a higher dosage 
of tamoxifen (40 mg/day) are more prone to 
develop more biologically aggressive tumors 
(Magriples et al. 1993).
Poor histologic phenotypes, including high-
grade serous, clear cell, mucinous, or aggressive 
endometrioid adenocarcinomas, have been reported 
to be associated with tamoxifen use (Silva et al. 
1994; Deligdisch et al. 2000; McCluggage et al. 
2003). Magriples et al. (1993) reported that 67% 
of the corpus cancers that developed in 15 tamox-
ifen-treated breast cancer patients were high-grade 
or unfavorable histologic subtypes, compared with 
24% of those that developed in 38 breast cancer 
patients who had not received tamoxifen. A large 
French case-control study analyzed 135 cases of 
endometrial cancer diagnosed after breast cancer 
and 467 matched controls (Mignotte et al. 1998). 
Breast cancer patients who developed endometrial 
cancer and had received tamoxifen had a more 
advanced disease and a poorer prognosis than those 
with endometrial cancer without prior tamoxifen 
treatment. Some authors conﬁ  rmed these ﬁ  ndings 
(Silva et al. 1994; Deligdisch et al. 2000), but oth-
ers did not (Barakat et al. 1994; Fisher et al. 1994; 
Rutqvist et al. 1995; Nishimura et al. 2001). 
Barakat et al. (1994) reported no differences in the 
stage, grade, or histologic subtype of endometrial 
carcinomas that develop in breast cancer patients. 
The NSABP B-14 showed that endometrial carci-
nomas occurring after tamoxifen therapy do not 
appear to be of a different type or have a worse 
prognosis than such tumors in non-tamoxifen-
treated patients (Fisher et al. 1994). If the effect of 
tamoxifen on the endometrium is that of an estro-
gen agonist, associated endometrial carcinomas 
could be expected to have prognostic characteris-
tics similar to those associated with unopposed 
estrogen use. However, the concomitant use of 
progesterone does not seem to prevent or reverse 
tamoxifen -associated endometrial changes (De 
Muylder et al. 1991).
It has been known that tamoxifen can stimulate 
the proliferation of certain endometrial cancer cell 
lines (Homesley, 1996). Immunohistochemical 
studies of the Ki67 index indicate that tamoxifen 
exerts an antiestrogenic effect on the endometrium 
in the presence of endogenous estrogen secretion 
and an estrogenic effect in the absence of estrogen 
secretion (Hachisuga et al. 1999). This mechanism 
is further supported by Cross et al. (1990), who 
described the occurrence of complex atypical 
hyperplasia in an ovariectomized premenopausal 
breast cancer patient undergoing tamoxifen treat-
ment. A recent study provides further documenta-
tion that the uterotrophic effect of tamoxifen on 
postmenopausal endometrium may be attributable 
to overexpression of both ERs and progesterone 
receptors (Elkas et al. 2000). Oncogene changes, 
such as K-ras mutation, c-erbB2/neu gene ampli-
ﬁ  cation, and cyclin D1 and p53 overexpression 
have also been observed in tamoxifen-related 
endometrial cancers (Esteller et al. 1997; Esteller 
et al. 1999; Boyd, 1996).
In addition to the fact that women with breast 
cancer are more likely to develop endometrial 
carcinoma, regardless of tamoxifen treatment, 
many reports published in recent years have dem-
onstrated a signiﬁ  cant association between longer 
duration of tamoxifen treatment and the appear-
ance of endometrial cancer (Fisher et al. 1994; 
Ismail, 1994; Jordan and Assikis, 1995; Rutqvist 
et al. 1995; Curtis et al. 1996; Fisher et al. 1998; 
Deligdisch et al. 2000). It is now generally 
accepted that stage, grade, histological type, and 
other prognostic factors of endometrial cancers 
associated with tamoxifen (20 mg/day) are not 27
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different from those of endometrial cancers found 
in the normal population tamoxifen (ACOG 
Committee Opinion, 1996; Homesley, 1996; Love 
et al. 1999). However, tamoxifen time- and dose-
dependently increases the relative risk for 
endometrial cancer (ACOG Committee Opinion, 
1996; MacGregor and Jordan, 1998; Love et al. 
1999). The long genesis of cancer in humans 
makes it likely that short courses of tamoxifen 
may condition the build-up of cancers that become 
clinically detectable later. It has been reported that 
the prognosis of endometrial cancer was signiﬁ  -
cantly worse for long-term tamoxifen users than 
for non-users, which seems to be due to higher 
stage and less-favorable histology, such as 
MMMTs or sarcomas, p53-positive tumors, and 
ER-negative tumors (Bergman et al. 2000).
Recent studies suggest that low- and high-risk 
groups of postmenopausal patients may be 
identifiable before the initiation of tamoxifen 
therapy for breast cancer (Berliere et al. 2000; 
Vosse et al. 2002). Pretreatment screening identi-
ﬁ  ed 85 asymptomatic patients with benign polyps 
in 510 postmenopausal patients with newly 
diagnosed breast cancer (16.7%). All polyps were 
removed. At the time of polypectomy, two patients 
had atypical hyperplasias and subsequently under-
went hysterectomies. The rest were treated with 
tamoxifen, 20 mg/day, for up to 5 years. The 
incidence of atypical hyperplasia was 11.7% in the 
group with initial lesions versus 0.7% in the group 
without lesions (p   0.0001), an 18-fold increase 
in risk. In addition, polyps developed in 17.6% of 
the group with initial lesions versus 12.9% in the 
group without.
In contrast to postmenopausal women, pre-
menopausal women treated with tamoxifen have 
no known increased risk of uterine cancer (ACOG 
Committee Opinion, 2000). Stackievicz et al. 
(2001) suggested that tamoxifen treatment acti-
vates apoptotic pathways in the endometrium of 
premenopausal women, and that the lack of a car-
cinogenic effect in hormonally active endometrium 
may be attributable to an active anti-cancerous 
process and not to menstrual shedding alone.
Uterine sarcomas consisting of mixed Müllerian 
tumors, leiomyosarcomas, and stromal cell sarco-
mas are a rare form of uterine malignancy occur-
ring in 2%–5% of all patients with uterine 
malignancies (Averette and Nguyen, 1995). The 
mixed Müllerian tumors consist of a glandular 
component that can be either benign (Müllerian 
adenosarcoma) or malignant (carcinosarcoma or 
MMMT), intermixed with nonepithelial elements 
that are either benign (carcinoﬁ  broma) or malignant 
(carcinosarcoma or MMMT). The mesenchymal 
component, whether benign or malignant, may 
exhibit homologous or heterologous differentiation 
(rhabdo-, lipo-, chondro-, or osteo-differentia-
tions). As both stromal cells and epithelial cells in 
the uterus express the ER (Vollmer et al. 1990), 
one might expect tamoxifen to increase the prolif-
eration of both elements, leading to epithelial, 
mesenchymal, or mixed epithelial-nonepithelial 
tumors.
In a review of all NSABP breast cancer treat-
ment trials, the rate of sarcoma in women treated 
with tamoxifen was 17 per 100,000 patient-years 
versus none in the placebo group (Wickerham et al. 
2002). Similarly, in a separate trial of high-risk 
women without breast cancer taking tamoxifen as 
part of a breast cancer prevention trial with a 
median follow-up of 6.9 years, there were 4 sar-
comas (17 per 100,000 patient years) in the 
tamoxifen group versus none in the placebo group 
(Wickerham et al. 2002). This is compared with 
the incidence of 1 to 2 per 100,000 patient years 
in the general population (Mouridsen et al. 1978). 
Many reports published in recent years have 
demonstrated a signiﬁ  cant association between 
longer duration of tamoxifen treatment and the 
appearance of uterine sarcoma (Bergman et al. 
2000; Lasset et al. 2001).
Most of the tamoxifen-associated sarcomas 
reported in the literature were MMMTs (Altaras 
et al. 1993; Lahti et al. 1993; Cohen et al. 1994a; 
ACOG Committee Opinion, 1996; Clement et al. 
1996; Curtis et al. 1996; Mourits et al. 1998; 
Deligdisch et al. 2000). Three cases of carcinosar-
coma in tamoxifen users were also reported 
(Treilleux et al. 1999).
Eight cases of uterine adenosarcomas were 
associated with tamoxifen therapy (Clement et al. 
1996; Mourits et al. 1998; Carvalho et al. 2000). 
Considering the rarity of this disease, it seems that 
the association of tamoxifen therapy with mesen-
chymal neoplasm is higher than expected.
Adenofibroma of the endometrium is an 
uncommon variant of mixed mesodermal tumors, 
in which the epithelial and stromal components 
are benign. It most commonly occurs in 
postmenopausal women (Zaloudek and Norris, 
1981). Five cases of uterine adenoﬁ  broma in a 
postmenopausal patient receiving tamoxifen were 28
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reported (Huang et al. 1996; Oshima et al. 2002; 
Hayasaka et al. 2006).
Endometrial stromal sarcoma is a rare uterine 
mesenchymal tumor reported to account for 0.2% 
of all uterine malignancies (Koss et al. 1965). 
Several cases of tamoxifen-associated endometrial 
stromal sarcoma in postmenopausal breast cancer 
patients have been reported in the literature (Fisher 
et al. 1994; Eddy and Mazur, 1997; Mignotte et al. 
1998; Wickerham et al. 2002; Saga et al. 2003; 
Sesti et al. 2005; Hayasaka et al. 2006). These 
tumors include high-grade endometrial stromal 
sarcoma (Saga et al. 2003; Sesti et al. 2005), as 
well as low-grade endometrial stromal sarcoma 
(Eddy and Mazur, 1997; Mignotte et al. 1998; 
Wickerham et al. 2002).
Leiomyoma
Tamoxifen has an estrogenic effect on the myome-
trium. Several studies have explained the increase 
in myometrial volume, and the growth of uterine 
leiomyomas in postmenopausal patients following 
the administration of tamoxifen (Dilts et al. 1992; 
Kedar et al. 1994; Cohen et al. 1994a; Leo et al. 
1994; Kang et al. 1996). The myomas grew rapidly 
after the initiation of tamoxifen treatment in the 
reported cases.
The leiomyomas observed in tamoxifen-treated 
women do not differ histologically from those 
found in untreated women (Ascher et al. 2000). 
Liu et al. (2006) reported a case of mitotically 
active leiomyoma in a postmenopausal patient 
receiving tamoxifen. Burroughs et al. (1997) 
showed that tamoxifen treatment does not change 
the apoptotic rate of leiomyoma tissues. They sug-
gested that growth modulation of leiomyoma by 
hormone modulation occurs via mechanisms inde-
pendent of apoptosis. They concluded that there is 
a fundamental difference between the response of 
leiomyoma to hormone deprivation and that of 
tumors of the breast.
As only a few reports have studied the effect of 
tamoxifen on leiomyomas, the frequency of symp-
tomatic uterine myomas and indications for surgery 
are unknown.
Uterine Cervix
During long-term use, tamoxifen use has estrogenic 
effects in squamous epithelial cells within the 
cervix in postmenopausal patients (Mourits et al. 
2001; Varras et al. 2003).
The association of tamoxifen with cervical 
polyps has been demonstrated by several studies 
(Varras et al. 2003). Lahti et al. (1993) found that 
endocervical polyps were twice as common in a 
tamoxifen-treated patients than in a control group. 
The relationship between tamoxifen use and the 
occurrence of cervical cancer has not been 
reported.
Vagina
The vagina is lined by stratiﬁ  ed squamous, non-
keratinizing epithelium containing ER in pre- and 
postmenopausal women (Wiegerink et al. 1980). 
The epithelium is multilayered and the cells in the 
middle and superﬁ  cial zones contain glycogen only 
when stimulated by estrogen. Under estrogenic 
stimulation, the vaginal epithelium undergoes 
proliferation and maturation.
Several studies have reported that tamoxifen 
exerts a weak estrogenic effect on the vaginal 
epithelium in postmenopausal patients during long-
term tamoxifen use (Lahti et al. 1994; Mourits et al. 
2001; Varras et al. 2003). The relationship between 
tamoxifen use and the occurrence of vaginal 
neoplasms has not been reported.
Tumor-Like Diseases
Endometriosis
The development of endometriosis has been 
reported in women receiving tamoxifen for the 
treatment of breast cancer (Ford et al. 1988; Cano 
et al. 1989; Hajjar et al. 1993; Cohen et al. 1994b; 
Morgan et al. 1994). A histopathologic analysis of 
endometriosis in a tamoxifen-treated, postmeno-
pausal breast cancer patient showed similarity to 
tamoxifen-induced epithelial differentiation of the 
endometrium (Ismail and Maulik, 1997). The 
development of endometriosis has been frequently 
reported in postmenopausal patients taking 
tamoxifen (Hajjar et al. 1993; Cohen et al. 1994b; 
Ismail and Maulik, 1997). Several cases of 
endometriosis in the ovary have also been described 
in premenopausal women during tamoxifen 
administration (Ford et al. 1988; Cano et al. 1989; 
Morgan et al. 1994).
Endometriosis is common in premenopausal 
women, and its occurrence in tamoxifen-treated 
women in this age group may therefore be coinci-
dental. In contrast, endometriosis is rare in 29
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postmenopausal women and the finding of 
endometriosis in tamoxifen-treated postmenopausal 
women raises the possibility of a link between 
tamoxifen use and endometriosis. This possibility 
is further supported by the unusual morphological 
features and behavior of endometriosis in tamoxi-
fen treated postmenopausal women (Hajjar et al. 
1993; Cohen et al. 1994a; Ismail and Maulik, 
1997). One patient had pelvic endometriosis inﬁ  l-
trating the cervix, vagina, rectum, and sigmoid 
colon (Hajjar et al. 1993). Another patient had a 
cystic ovarian endometriotic cyst with apparent 
infiltration of adjacent structures (Ismail and 
Maulik, 1997). Another patient developed an 
ovarian endometrioid adenocarcinoma in an 
endometriotic cyst (Cohen et al. 1994b), suggesting 
that prolonged tamoxifen treatment may be 
associated with an increased risk of carcinoma 
arising in endometriotic foci.
As endometriosis is an estrogen-dependent 
disease, the mechanism by which tamoxifen acts 
probably that its estrogen agonistic activity stimu-
lates the ectopic endometriotic tissue even in 
postmenopausal women. However, it is not clear 
whether tamoxifen causes de novo endometriosis 
or only exacerbates preexisting endometriosis.
Adenomyosis
Several cases of adenomyosis have been reported 
as having developed in postmenopausal patients 
during tamoxifen administration (Cohen et al. 
1995; Cohen et al. 1997). Cohen et al. (1997) 
found a higher incidence of adenomyosis 
(53.6%) in postmenopausal breast cancer 
patients treated with tamoxifen than in those not 
receiving the drug.
The morphological features present within 
adenomyosis more often in those taking tamoxifen 
were cystic dilatation of glands, fibrosis of the 
stroma, and various epithelial metaplasias 
(McCluggage et al. 2000). The proliferative activity 
within the adenomyosis was higher in the tamoxifen 
group. In postmenopausal tamoxifen-treated patients, 
ERs and PRs have been described in adenomyosis 
in similar concentrations as in premenopausal non-
tamoxifen users (Cohen et al. 1998b).
Conclusions
As reviewed in this paper, tamoxifen has been 
demonstrated to induce tumorigenesis in the 
female genital tract through estrogen agonism. 
Of the tamoxifen-associated pathologies dis-
cussed above, practitioners should be aware of 
the occurrence of endometrial diseases in post-
menopausal women and ovarian functional cysts 
in premenopausal women. Tamoxifen is associ-
ated with an increased incidence of benign endo-
metrial lesions, such as polyps and hyperplasia, 
as well as with a two- to three-fold increased risk 
of endometrial cancer in postmenopausal patients. 
Practitioners should be aware of the occurrence 
of endometrial diseases, and diagnostic proce-
dures should be performed at the discretion of 
the individual gynecologist. However, there is 
no general consensus regarding endometrial 
surveillance in postmenopausal tamoxifen users. 
The most important recommendation by the 
ACOG is to thoroughly evaluate any discharge 
or bleeding by means of endometrial biopsy in 
women treated with tamoxifen (ACOG Commit-
tee Opinion, 2006) (Table 2). The risk of func-
tional ovarian cysts is significantly high in 
premenopausal tamoxifen users. Cohen et al. 
(1994) suggested that all premenopausal breast 
cancer patients being treated with tamoxifen 
should be under close gynecological and ultra-
sonographic surveillance. We recommend that 
gynecological, cytological, and ultrasonographic 
examination should be performed every 4–6 
months for the women receiving tamoxifen. In 
case of abnormal observations, further examina-
tion is necessary for the denial of malignan-
cies.
Despite its gynecologic side effects, beneﬁ  ts of 
tamoxifen in pre- and postmenopausal breast 
cancer patients in controlling breast cancer or 
preventing its relapse are without debate. Therefore, 
there is a clear need to elucidate the mechanism 
underlying action of tamoxifen in the reproductive 
tract. Genital side effects of tamoxifen are an 
example of the complexity of its mechanism of 
action, with agonistic and antagonistic effects 
on various sites and tissues, dependent on the 
ambient E2 concentration. Frequent gyneco-
logical examination including transvaginal 
ultrasonography should be performed for both 
premenopausal and postmenopausal tamoxifen-
treated patients. The multidisciplinary team 
including the surgeon, oncologist, and the 
patient’s primary care physician should be famil-
iar with these gynecologic complications of 
tamoxifen therapy. Further research will enable 
the prediction of which groups of patients are 30
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more susceptible to develop pathologies of the 
genital tract.
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